{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "32298294", "DateCompleted": {"Year": "2020", "Month": "07", "Day": "27"}, "DateRevised": {"Year": "2020", "Month": "07", "Day": "27"}, "Article": {"ArticleDate": [{"Year": "2020", "Month": "04", "Day": "16"}], "Language": ["eng"], "ELocationID": ["e0231466", "10.1371/journal.pone.0231466"], "Journal": {"ISSN": "1932-6203", "JournalIssue": {"Volume": "15", "Issue": "4", "PubDate": {"Year": "2020"}}, "Title": "PloS one", "ISOAbbreviation": "PLoS One"}, "ArticleTitle": "DaHuangWan targets EGF signaling to inhibit the proliferation of hepatoma cells.", "Pagination": {"StartPage": "e0231466", "MedlinePgn": "e0231466"}, "Abstract": {"AbstractText": ["DaHuangWan (DHW) is a traditional herbal medicine used by Mongolian to treat liver cancer for many years. Clinical application of the drug has been shown to help control tumor progression, prolong survival and improve quality of life. However, the underlying mechanisms and side effects of this drug remain unclear, which greatly limits the clinical application and further optimization of DHW. In this study, we found that DHW inhibits the proliferation of hepatoma cells by modulating the epithelial growth factor (EGF) signaling pathway. Berberine and Costunolide are the main active ingredients in DHW. Interestingly, the combination of Berberine and Costunolide has a dramatic synergistic effect on inhibiting the proliferation of hepatoma cells. Neither Berberine nor Costunolide directly block EGFR phosphorylation. Berberine promotes endocytosis of activated EGFR, while as Costunolide increases ubiquitination of EGFR and reduces EGFR recycling to cell membrane distribution, thereby inhibiting EGF signaling. Berberine and Costunolide target two different steps in regulating the EGF signaling, which explains the synergistic anti-cancer effect of DHW. Since Berberine and Costunolide do not directly target EGFR phosphorylation, DHW could be a supplementary medicine to tyrosine kinase inhibitors in cancer therapy."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Affiliated Hospital of Inner Mongolia University for the Nationalities, Tongliao, Inner Mongolia, China."}, {"Identifier": [], "Affiliation": "Inner Mongolia University for the Nationalities, Tongliao, Inner Mongolia, China."}, {"Identifier": [], "Affiliation": "National Center for Liver Cancer, Eastern Hepatobiliary Surgery Hospital/Institute, the Second Military Medical University, Shanghai, China."}], "LastName": "Si", "ForeName": "Ha", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Inner Mongolia University for the Nationalities, Tongliao, Inner Mongolia, China."}], "LastName": "Genna", "ForeName": "Ba", "Initials": "B"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "National Center for Liver Cancer, Eastern Hepatobiliary Surgery Hospital/Institute, the Second Military Medical University, Shanghai, China."}], "LastName": "Zhuang", "ForeName": "Xiangjin", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "National Center for Liver Cancer, Eastern Hepatobiliary Surgery Hospital/Institute, the Second Military Medical University, Shanghai, China."}, {"Identifier": [], "Affiliation": "Division of Life Sciences and Medicine, Cancer Research Center, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, Anhui, China."}], "LastName": "Wang", "ForeName": "Jing", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Affiliated Hospital of Inner Mongolia University for the Nationalities, Tongliao, Inner Mongolia, China."}], "LastName": "Burenbatu", "ForeName": "B", "Initials": "B"}, {"Identifier": ["0000-0003-2715-0087"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "National Center for Liver Cancer, Eastern Hepatobiliary Surgery Hospital/Institute, the Second Military Medical University, Shanghai, China."}], "LastName": "Feng", "ForeName": "Qiyu", "Initials": "Q"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "National Center for Liver Cancer, Eastern Hepatobiliary Surgery Hospital/Institute, the Second Military Medical University, Shanghai, China."}], "LastName": "Wang", "ForeName": "Hongyang", "Initials": "H"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "PLoS One", "NlmUniqueID": "101285081", "ISSNLinking": "1932-6203"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Sesquiterpenes"}, {"RegistryNumber": "0I8Y3P32UF", "NameOfSubstance": "Berberine"}, {"RegistryNumber": "4IK578SA7Z", "NameOfSubstance": "costunolide"}, {"RegistryNumber": "62229-50-9", "NameOfSubstance": "Epidermal Growth Factor"}], "MeshHeadingList": [{"QualifierName": ["drug effects"], "DescriptorName": "Apoptosis"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Berberine"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Carcinoma, Hepatocellular"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Cycle"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Proliferation"}, {"QualifierName": ["antagonists & inhibitors"], "DescriptorName": "Epidermal Growth Factor"}, {"QualifierName": [], "DescriptorName": "Flow Cytometry"}, {"QualifierName": ["methods"], "DescriptorName": "Herbal Medicine"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Liver Neoplasms"}, {"QualifierName": ["methods"], "DescriptorName": "Medicine, East Asian Traditional"}, {"QualifierName": [], "DescriptorName": "Mongolia"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Sesquiterpenes"}], "CoiStatement": "The authors declare no potential conflicts of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, et al. (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68: 394\u2013424. 10.3322/caac.21492", "ArticleIdList": ["10.3322/caac.21492", "30207593"]}, {"Citation": "Llovet JM, Villanueva A, Lachenmayer A, Finn RS (2015) Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol 12: 408\u2013424. 10.1038/nrclinonc.2015.103", "ArticleIdList": ["10.1038/nrclinonc.2015.103", "26054909"]}, {"Citation": "HanZhiqiang HS (2017) Study on the Optimum Extraction Technology for Mongolian Medicine Runing Granules Traditional Medical Science and Tecnology 24: 46\u201348."}, {"Citation": "Yang WJ, Li DP, Li JK, Li MH, Chen YL, et al. (2009) Synergistic antioxidant activities of eight traditional Chinese herb pairs. Biol Pharm Bull 32: 1021\u20131026. 10.1248/bpb.32.1021", "ArticleIdList": ["10.1248/bpb.32.1021", "19483308"]}, {"Citation": "Tang J, Feng Y, Tsao S, Wang N, Curtain R, et al. (2009) Berberine and Coptidis rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations. J Ethnopharmacol 126: 5\u201317. 10.1016/j.jep.2009.08.009", "ArticleIdList": ["10.1016/j.jep.2009.08.009", "19686830"]}, {"Citation": "Wang N, Feng Y, Lau EP, Tsang C, Ching Y, et al. (2010) F-actin reorganization and inactivation of rho signaling pathway involved in the inhibitory effect of Coptidis Rhizoma on hepatoma cell migration. Integr Cancer Ther 9: 354\u2013364. 10.1177/1534735410379121", "ArticleIdList": ["10.1177/1534735410379121", "21106616"]}, {"Citation": "Hou Q, Tang X, Liu H, Tang J, Yang Y, et al. (2011) Berberine induces cell death in human hepatoma cells in vitro by downregulating CD147. Cancer Sci 102: 1287\u20131292. 10.1111/j.1349-7006.2011.01933.x", "ArticleIdList": ["10.1111/j.1349-7006.2011.01933.x", "21443647"]}, {"Citation": "Yoshikawa M, Hatakeyama S, Inoue Y, Yamahara J (1993) Saussureamines A, B, C, D, and E, new anti-ulcer principles from Chinese Saussureae Radix. Chem Pharm Bull (Tokyo) 41: 214\u2013216.", "ArticleIdList": ["8448819"]}, {"Citation": "Choi JY, Na M, Hyun Hwang I, Ho Lee S, Young Bae E, et al. (2009) Isolation of betulinic acid, its methyl ester and guaiane sesquiterpenoids with protein tyrosine phosphatase 1B inhibitory activity from the roots of Saussurea lappa C.B.Clarke. Molecules 14: 266\u2013272. 10.3390/molecules14010266", "ArticleIdList": ["10.3390/molecules14010266", "PMC6267619", "19136914"]}, {"Citation": "Hasson SS, AS HA-S, Al-Busaidi JZ, Al-Balushi MS, Hakkim FL, et al. (2018) Potential of Aucklandia Lappa Decne Ethanolic Extract to Trigger Apoptosis of Human T47D and Hela Cells. Asian Pac J Cancer Prev 19: 1917\u20131925. 10.22034/APJCP.2018.19.7.1917", "ArticleIdList": ["10.22034/APJCP.2018.19.7.1917", "PMC6165671", "30051673"]}, {"Citation": "Tian X, Song HS, Cho YM, Park B, Song YJ, et al. (2017) Anticancer effect of Saussurea lappa extract via dual control of apoptosis and autophagy in prostate cancer cells. Medicine (Baltimore) 96: 30(e7606).", "ArticleIdList": ["PMC5627836", "28746210"]}, {"Citation": "Moon SM, Yun SJ, Kook JK, Kim HJ, Choi MS, et al. (2013) Anticancer activity of Saussurea lappa extract by apoptotic pathway in KB human oral cancer cells. Pharm Biol 51: 1372\u20131377. 10.3109/13880209.2013.792847", "ArticleIdList": ["10.3109/13880209.2013.792847", "23855888"]}, {"Citation": "Seo CS, Lim HS, Jeong SJ, Shin HK (2015) Anti-allergic effects of sesquiterpene lactones from the root of Aucklandia lappa Decne. Mol Med Rep 12: 7789\u20137795. 10.3892/mmr.2015.4342", "ArticleIdList": ["10.3892/mmr.2015.4342", "26398906"]}, {"Citation": "Singireesu S, Misra S, Mondal SK, Yerramsetty S, Sahu N, et al. (2018) Costunolide induces micronuclei formation, chromosomal aberrations, cytostasis, and mitochondrial-mediated apoptosis in Chinese hamster ovary cells. Cell Biol Toxicol 34: 125\u2013142. 10.1007/s10565-017-9411-z", "ArticleIdList": ["10.1007/s10565-017-9411-z", "28914393"]}, {"Citation": "Wang Z, Zhao X, Gong X (2016) Costunolide induces lung adenocarcinoma cell line A549 cells apoptosis through ROS (reactive oxygen species)-mediated endoplasmic reticulum stress. Cell Biol Int 40: 289\u2013297. 10.1002/cbin.10564", "ArticleIdList": ["10.1002/cbin.10564", "26609913"]}, {"Citation": "Hua P, Zhang G, Zhang Y, Sun M, Cui R, et al. (2016) Costunolide induces G1/S phase arrest and activates mitochondrial-mediated apoptotic pathways in SK-MES 1 human lung squamous carcinoma cells. Oncol Lett 11: 2780\u20132786. 10.3892/ol.2016.4295", "ArticleIdList": ["10.3892/ol.2016.4295", "PMC4812560", "27073552"]}, {"Citation": "Hua P, Sun M, Zhang G, Zhang Y, Song G, et al. (2016) Costunolide Induces Apoptosis through Generation of ROS and Activation of P53 in Human Esophageal Cancer Eca-109 Cells. J Biochem Mol Toxicol 30: 462\u2013469. 10.1002/jbt.21810", "ArticleIdList": ["10.1002/jbt.21810", "27078502"]}, {"Citation": "Yang YI, Kim JH, Lee KT, Choi JH (2011) Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species. Gynecol Oncol 123: 588\u2013596. 10.1016/j.ygyno.2011.08.031", "ArticleIdList": ["10.1016/j.ygyno.2011.08.031", "21945308"]}, {"Citation": "Kim JH, Yang YI, Lee KT, Park HJ, Choi JH (2011) Costunolide induces apoptosis in human endometriotic cells through inhibition of the prosurvival Akt and nuclear factor kappa B signaling pathway. Biol Pharm Bull 34: 580\u2013585. 10.1248/bpb.34.580", "ArticleIdList": ["10.1248/bpb.34.580", "21467650"]}, {"Citation": "Lemmon MA, Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell 141: 1117\u20131134. 10.1016/j.cell.2010.06.011", "ArticleIdList": ["10.1016/j.cell.2010.06.011", "PMC2914105", "20602996"]}, {"Citation": "Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, et al. (2006) Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366: 2\u201316. 10.1016/j.gene.2005.10.018", "ArticleIdList": ["10.1016/j.gene.2005.10.018", "16377102"]}, {"Citation": "Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, et al. (2012) Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 16: 15\u201331. 10.1517/14728222.2011.648617", "ArticleIdList": ["10.1517/14728222.2011.648617", "PMC3291787", "22239438"]}, {"Citation": "Miyamoto Y, Suyama K, Baba H (2017) Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer. Int J Mol Sci 18: 752\u201315.", "ArticleIdList": ["PMC5412337", "28368335"]}, {"Citation": "Hou Y, Zhou M, Xie J, Chao P, Feng Q, et al. (2017) High glucose levels promote the proliferation of breast cancer cells through GTPases. Breast Cancer (Dove Med Press) 9: 429\u2013436.", "ArticleIdList": ["PMC5479300", "28670141"]}, {"Citation": "Conte A, Sigismund S (2017) Methods to Investigate EGFR Ubiquitination. Methods Mol Biol 1652: 81\u2013100. 10.1007/978-1-4939-7219-7_5", "ArticleIdList": ["10.1007/978-1-4939-7219-7_5", "28791635"]}, {"Citation": "Conte A, Sigismund S (2016) Chapter Six\u2014The Ubiquitin Network in the Control of EGFR Endocytosis and Signaling. Prog Mol Biol Transl Sci 141: 225\u2013276. 10.1016/bs.pmbts.2016.03.002", "ArticleIdList": ["10.1016/bs.pmbts.2016.03.002", "27378759"]}, {"Citation": "Lei CT, Wei YH, Tang H, Wen Q, Ye C, et al. (2017) PKC-alpha Triggers EGFR Ubiquitination, Endocytosis and ERK Activation in Podocytes Stimulated with High Glucose. Cell Physiol Biochem 42: 281\u2013294. 10.1159/000477329", "ArticleIdList": ["10.1159/000477329", "28535513"]}, {"Citation": "Pinilla-Macua I, Sorkin A (2015) Methods to study endocytic trafficking of the EGF receptor. Methods Cell Biol 130: 347\u2013367. 10.1016/bs.mcb.2015.05.008", "ArticleIdList": ["10.1016/bs.mcb.2015.05.008", "PMC4836846", "26360045"]}, {"Citation": "N.P C (2015) PharmacopoeiaPeople\u2019s Repub.China.: 64\u2013303."}, {"Citation": "Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70: 440\u2013446. 10.1158/0008-5472.CAN-09-1947", "ArticleIdList": ["10.1158/0008-5472.CAN-09-1947", "20068163"]}, {"Citation": "Miyamoto Y, Suyama K, Baba H (2017) Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer. Int J Mol Sci 18: 15.", "ArticleIdList": ["PMC5412337", "28368335"]}, {"Citation": "Jie S, Li H, Tian Y, Guo D, Zhu J, et al. (2011) Berberine inhibits angiogenic potential of Hep G2 cell line through VEGF down-regulation in vitro. J Gastroenterol Hepatol 26: 179\u2013185. 10.1111/j.1440-1746.2010.06389.x", "ArticleIdList": ["10.1111/j.1440-1746.2010.06389.x", "21175812"]}, {"Citation": "Dong GZ, Shim AR, Hyeon JS, Lee HJ, Ryu JH (2015) Inhibition of Wnt/beta-Catenin Pathway by Dehydrocostus Lactone and Costunolide in Colon Cancer Cells. Phytother Res 29: 680\u2013686. 10.1002/ptr.5299", "ArticleIdList": ["10.1002/ptr.5299", "25625870"]}], "ReferenceList": []}], "History": [{"Year": "2019", "Month": "12", "Day": "25"}, {"Year": "2020", "Month": "3", "Day": "24"}, {"Year": "2020", "Month": "4", "Day": "17", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "4", "Day": "17", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "7", "Day": "28", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "4", "Day": "16"}], "PublicationStatus": "epublish", "ArticleIdList": ["32298294", "PMC7161984", "10.1371/journal.pone.0231466", "PONE-D-19-35686"]}}], "PubmedBookArticle": []}